Differential expression of the mannose 6-phosphate/ insulin-like growth factor-II receptor in human breast cancer cell lines of different invasive potential.
BACKGROUND
Hypersecretion of the precursor of the lysosomal protease cathepsin D (procathepsin D) has been implicated in the invasive phenotype of human breast cancer. However, the mechanism of the abnormal secretion of procathepsin D remains unclear. Since the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a central role in the intracellular transport and endocytosis of M6P-containing lysosomal enzymes, a deficiency in functional M6P/IGF2R may underlie the hypersecretion of procathepsin D in invasive tumors.


METHODS
In the present study, we compared the profiles of cathepsin D and the M6P/IGF2R between the highly invasive MDA-MB-231 and the non-invasive MCF-7 cell lines.


RESULTS
MDA-MB-231cells were confirmed to secrete a much larger proportion of procathepsin D into the medium than MCF-7 cells. Addition of M6P to the culture medium significantly altered the secretion of procathepsin D by MCF-7 cells, but had little effect on cathepsin D distribution in MDA-MB-231cells. Both the M6P-binding capacity and the endocytosis of exogenous M6P-bearing proteins in MDA-MB-231 cells were far less than those in MCF-7 cells. mRNA analysis indicated that the levels of the M6P/IGF2R mRNA in MDA-MB-231 cells were not lower but were even higher than that in MCF-7 cells. Sequence analysis indicated a difference in the 3'-untranslated region of M6P/IGF2R between the two cell lines, but no mutation in the M6P-binding domain of the receptor.


CONCLUSIONS
The results suggest that a potential defect in a post-transcriptional process (e.g., translation) may exist during synthesis of the M6P/IGF2R in MDA-MB-231cells, leading to failure to express sufficient functional M6P/IGF2R and thereby resulting in the hypersecretion of procathepsin D.
Xie
Suqing
S
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. kang.jing@mgh.harvard.edu
Kang
Jing X
JX
D020413:3' Untranslated Regions / Q000235:genetics; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D002402:Cathepsin D / Q000378:metabolism*; D004792:Enzyme Precursors / Q000378:metabolism*; D005260:Female; D006801:Humans; D009154:Mutation; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017527:Receptor, IGF Type 2 / Q000235:genetics / Q000378:metabolism*; D017422:Sequence Analysis, DNA; D014407:Tumor Cells, Cultured
D020413:3' Untranslated Regions; D004792:Enzyme Precursors; D012333:RNA, Messenger; D017527:Receptor, IGF Type 2; D002402:Cathepsin D